Evidence map›Paper›PMID 34830724›Full record

ArticleJournal of clinical medicine2021

Wearable Cardioverter-Defibrillator Used as a Telemonitoring System in a Real-Life Heart Failure Unit Setting.

Christian Blockhaus, Stephan List, Hans-Peter Waibler, Jan-Erik Gülker, Heinrich Klues, Alexander Bufe, Melchior Seyfarth, Buelent Koektuerk, Dong-In Shin

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christian BlockhausHeart Centre Niederrhein, Department of Cardiology, Helios Clinic Krefeld, 47805 Krefeld, Germany.ORCID 0000-0001-6962-9163
Stephan ListHeart Centre Niederrhein, Department of Cardiology, Helios Clinic Krefeld, 47805 Krefeld, Germany.
Hans-Peter WaiblerHeart Centre Niederrhein, Department of Cardiology, Helios Clinic Krefeld, 47805 Krefeld, Germany.
Jan-Erik GülkerWitten-Herdecke University, 58455 Witten, Germany.
Heinrich KluesHeart Centre Niederrhein, Department of Cardiology, Helios Clinic Krefeld, 47805 Krefeld, Germany.
Alexander BufeHeart Centre Niederrhein, Department of Cardiology, Helios Clinic Krefeld, 47805 Krefeld, Germany.
Melchior SeyfarthWitten-Herdecke University, 58455 Witten, Germany.ORCID 0000-0002-9473-8262
Buelent KoektuerkHeart Centre Niederrhein, Department of Cardiology, Helios Clinic Krefeld, 47805 Krefeld, Germany.
Dong-In ShinHeart Centre Niederrhein, Department of Cardiology, Helios Clinic Krefeld, 47805 Krefeld, Germany.ORCID 0000-0002-8804-933X

Funding

Helios Kliniken 2020-0257
6 · The paper itself

Abstract

backgroundIn patients with reduced left ventricular ejection fraction (LVEF) who are at risk of sudden cardiac death, a wearable cardioverter-defibrillator (WCD) is recommended as a bridge to the recovery of LVEF or as a bridge to the implantation of a device. In addition to its function to detect and treat malignant arrhythmia, WCD can be used via an online platform as a telemonitoring system to supervise patients' physical activity, compliance, and heart rate.

methodsWe retrospectively analyzed 173 patients with regard to compliance and heart rate after discharge.

resultsMean WCD wearing time was 59.75 ± 35.6 days; the daily wearing time was 21.19 ± 4.65 h. We found significant differences concerning the patients' compliance. Men showed less compliance than women, and younger patients showed less compliance than patients who were older. Furthermore, we analyzed the heart rate from discharge until the end of WCD prescription and found a significant decrease from discharge to 4, 8, or 12 weeks.

conclusionWCD can be used as a telemonitoring system to help the involved heart failure unit or physicians attend to and adjust the medical therapy. Furthermore, specific patient groups should be educated more intensively with respect to compliance.

Indexed as

heart failure unitsudden cardiac deathtelemonitoringwearable cardioverter-defibrillator

Identifiers

PMID34830724
PMCPMC8618886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.